Gozzi M, Malfacini D, Albanese V, Pacifico S, Preti D, Guerrini R
RSC Med Chem. 2025; .
PMID: 39790123
PMC: 11707527.
DOI: 10.1039/d4md00747f.
Puls K, Olive-Marti A, Hongnak S, Lamp D, Spetea M, Wolber G
J Med Chem. 2024; 67(16):13788-13801.
PMID: 39088801
PMC: 11345774.
DOI: 10.1021/acs.jmedchem.4c00590.
Meqbil Y, Aguilar J, Blaine A, Chen L, Cassell R, Pradhan A
J Pharmacol Exp Ther. 2024; 389(3):301-309.
PMID: 38621994
PMC: 11125782.
DOI: 10.1124/jpet.123.001735.
Ding H, Kiguchi N, Dobbins M, Romero-Sandoval E, Kishioka S, Ko M
Drugs. 2023; 83(9):771-793.
PMID: 37209211
PMC: 10948013.
DOI: 10.1007/s40265-023-01878-5.
El Daibani A, Che T
Molecules. 2022; 27(3).
PMID: 35163856
PMC: 8838650.
DOI: 10.3390/molecules27030595.
Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.
Ubaldi M, Cannella N, Borruto A, Petrella M, Micioni Di Bonaventura M, Soverchia L
Int J Mol Sci. 2021; 22(23).
PMID: 34884757
PMC: 8657682.
DOI: 10.3390/ijms222312956.
Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.
Neve J, Barlow T, Tourwe D, Bihel F, Simonin F, Ballet S
RSC Med Chem. 2021; 12(6):828-870.
PMID: 34223156
PMC: 8221262.
DOI: 10.1039/d1md00041a.
Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists.
Azevedo Neto J, Ruzza C, Sturaro C, Malfacini D, Pacifico S, Zaveri N
Front Neurosci. 2021; 15:657153.
PMID: 33859548
PMC: 8042269.
DOI: 10.3389/fnins.2021.657153.
Biased Opioid Ligands.
Faouzi A, Varga B, Majumdar S
Molecules. 2020; 25(18).
PMID: 32948048
PMC: 7570672.
DOI: 10.3390/molecules25184257.
Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.
Calo G, Lambert D
Br J Anaesth. 2018; 121(5):1105-1114.
PMID: 30336855
PMC: 6208290.
DOI: 10.1016/j.bja.2018.06.024.
In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.
Ferrari F, Malfacini D, Journigan B, Bird M, Trapella C, Guerrini R
Pharmacol Res Perspect. 2017; 5(4).
PMID: 28805972
PMC: 5684865.
DOI: 10.1002/prp2.333.
Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.
Pacifico S, Carotenuto A, Brancaccio D, Novellino E, Marzola E, Ferrari F
Sci Rep. 2017; 7:45817.
PMID: 28383520
PMC: 5382891.
DOI: 10.1038/srep45817.
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
Toll L, Bruchas M, Calo G, Cox B, Zaveri N
Pharmacol Rev. 2016; 68(2):419-57.
PMID: 26956246
PMC: 4813427.
DOI: 10.1124/pr.114.009209.
Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.
Zaveri N
J Med Chem. 2016; 59(15):7011-28.
PMID: 26878436
PMC: 5001850.
DOI: 10.1021/acs.jmedchem.5b01499.
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri N
Neuropharmacology. 2016; 105:434-442.
PMID: 26867504
PMC: 5567672.
DOI: 10.1016/j.neuropharm.2016.02.003.
Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2.
Malfacini D, Ambrosio C, Gro M, Sbraccia M, Trapella C, Guerrini R
PLoS One. 2015; 10(8):e0132865.
PMID: 26248189
PMC: 4527783.
DOI: 10.1371/journal.pone.0132865.
Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.
Daga P, Zaveri N
Proteins. 2012; 80(8):1948-61.
PMID: 22489047
PMC: 3393802.
DOI: 10.1002/prot.24077.
The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
Zaveri N
Curr Top Med Chem. 2010; 11(9):1151-6.
PMID: 21050175
PMC: 3899399.
DOI: 10.2174/156802611795371341.
UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.
Calo G, Rizzi A, Cifani C, Micioni Di Bonaventura M, Regoli D, Massi M
CNS Neurosci Ther. 2010; 17(3):178-98.
PMID: 20497197
PMC: 6493780.
DOI: 10.1111/j.1755-5949.2009.00107.x.
The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity.
Shoblock J
CNS Drug Rev. 2007; 13(1):107-36.
PMID: 17461893
PMC: 6494153.
DOI: 10.1111/j.1527-3458.2007.00007.x.